Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit from immunotherapy.
Neurodegenerative Disease Research Inc. has made a five-year, $12.5 million philanthropic commitment to Northwestern to support research in amyotrophic lateral sclerosis (ALS) led by Teepu Siddique, MD.
Northwestern Medicine scientists continue to tackle every facet of the COVID-19 pandemic, from investigating coronavirus vaccines’ potential for providing immunity against similar coronaviruses to developing novel rapid antigen-based tests and examining disparities in COVID-19 case and mortality rates in Chicago.
Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved heart failure-related symptoms and physical limitations in patients with heart failure with preserved ejection fraction.
Scientists have discovered a potential biomarker that could more accurately identify which patients with non-hypermutated cancers will respond to specialized immunotherapy drugs.
A combination of drugs could fix the broken lysosomal enzyme pathway in Parkinson’s disease-afflicted neurons, according to a recent study.
Dr. Dinee Simpson, a transplant surgeon at Northwestern Medicine in Chicago, recalled a troubling example from a committee meeting early in her surgical training.[…]Hispanic patients are about half as likely as their white peers to receive kidney donations from family or friends — a gap that Dr. Juan Carlos Caicedo, an adult and pediatric transplant surgeon who directs the Hispanic Transplant Program at Northwestern Medicine, is working to close.
“Unfortunately, PE can strike people at all stages of life, from the young and healthy to the older and not as healthy,” said Dr. Karlyn Martin, an assistant professor of medicine at Northwestern University Feinberg School of Medicine in Chicago.
“Because these antibody levels are so robust, the booster could potentially give us protection for a longer duration than what we saw for two doses of the vaccine,” study co-author Alexis Demonbreun said in a Northwestern University news release. […]Co-author Thomas McDade said the findings are relevant to anyone who is considering a booster shot.
“This is too late,” said Dr. Robert Murphy, executive director of the Institute for Global Health at the Northwestern University Feinberg School of Medicine and a professor of infectious diseases. “What is the problem in getting the best treatment out there quickly?”